Bris­tol-My­ers shares drop; Re­gen­era of­fers a life­line to sink­ing Al­co­bra

→  The re­ver­ber­a­tions con­tin­ue from Bris­tol-My­ers Squibb’s mis­steps with Op­di­vo ear­li­er this year. Shares dropped four per­cent this week as ru­mors of a po­ten­tial sale once again be­gan to swirl, Bloomberg re­ports.  Im­muno-on­col­o­gy and drug com­bi­na­tions are pri­ma­ry fo­cus­es for Bris­tol-My­ers Squibb.

→  Re­gen­era share­hold­ers have of­fered to buy shares of Al­co­bra for 66.6% of the com­bined com­pa­ny. Al­co­bra is run­ning out of op­tions since it hasn’t re­cov­ered from the fail­ure of its AD­HD drug in Sep­tem­ber 2014.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.